Download PDF
Semin Thromb Hemost 2006; 32: 003-009
DOI: 10.1055/s-2006-946908
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Hemophilia Therapy and Blood-Borne Pathogen Risk

Richard Knight1 , Samuel Stanley2 , Michael Wong3 , Gerard Dolan4
  • 1National CJD Surveillance Unit, Edinburgh, United Kingdom
  • 2Washington University School of Medicine, St. Louis, Missouri
  • 3Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
  • 4University Hospital Nottingham, Nottingham, United Kingdom
Further Information

Publication History

Publication Date:
21 November 2006 (online)

    Permissions and Reprints

ABSTRACT

For a brief period, modern medical science was considered to have relegated infectious disease to that of a minor clinical challenge. However, several infectious diseases have emerged or re-emerged in recent years, raising epidemiological concerns, as well as issues over the availability of effective measures of control and treatment. Invariably, these infectious agents have been studied carefully in relation to the safety of blood products, often resulting in concern and action. Emerging diseases arise from many sources. Some are the result of viruses crossing the species barrier from animals to humans. In addition, combinations of these newly identified viruses may make each more difficult to treat, as in the case of human immunodeficiency virus and hepatitis C virus coinfection. Still others can arise from completely new biological mechanisms, such as the prion disease variant Creutzfeldt-Jacob disease, which has spread from infected cattle to humans, particularly in the United Kingdom. The emergence of new viruses and new disease sources has had a significant impact on coagulation factor therapies and blood donation policies. We must deal with these multiple threats and their potential to compromise the safety of our blood supply.

KEYWORDS

Emerging diseases - blood safety - variant Creutzfeldt-Jacob disease (vCJD) - blood transmission

REFERENCES

  • 1 Johnson R T. Emerging viral infections of the nervous system.  J Neurovirol. 2003;  9 140-147
    PubMedGoogle Scholar
  • 2 Appel M J, Scott F W, Carmichael L E. Isolation and immunisation studies of a canine parvo-like virus from dogs with haemorrhagic enteritis.  Vet Rec. 1979;  105 156-159
    CrossrefPubMedGoogle Scholar
  • 3 Chong H T, Kunjapan S R, Thayaparan T et al.. Nipah encephalitis outbreak in Malaysia, clinical features in patients from Seremban.  Can J Neurol Sci. 2002;  29 83-87
    PubMedGoogle Scholar
  • 4 Tan C T, Goh K J, Wong K T et al.. Relapsed and late-onset Nipah encephalitis.  Ann Neurol. 2002;  51 703-708
    CrossrefPubMedGoogle Scholar
  • 5 Chua K B, Goh K J, Wong K T et al.. Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia.  Lancet. 1999;  354 1257-1259
    CrossrefPubMedGoogle Scholar
  • 6 WHO .Nipah Virus. Fact Sheet Number 262. Revised. Geneva, Switzerland; World Health Organization September 2001
    Google Scholar
  • 7 Tan C T, Wong K T. Nipah encephalitis outbreak in Malaysia.  Ann Acad Med Singapore. 2003;  32 112-117
    PubMedGoogle Scholar
  • 8 Ai S Y. Profile of a virus. http://Available at: http:agrolink.moa.my/jph/dvs/nipah/star000410/nipah-profile.html Accessed October 3, 2005
    Google Scholar
  • 9 Buonavoglia C, Martella V, Pratelli A et al.. Evidence for evolution of canine parvovirus type 2 in Italy.  J Gen Virol. 2001;  82 3021-3025
    PubMedGoogle Scholar
  • 10 Cohen B. Parvovirus B19: an expanding spectrum of disease.  BMJ. 1995;  311 1549-1552
    PubMedGoogle Scholar
  • 11 Steinel A, Parrish C R, Bloom M E, Truyen U. Parvovirus infections in wild carnivores.  J Wildl Dis. 2001;  37 594-607
    PubMedGoogle Scholar
  • 12 Heegaard E D, Brown K E. Human parvovirus B19.  Clin Microbiol Rev. 2002;  15 485-505
    CrossrefPubMedGoogle Scholar
  • 13 Santagostino E, Mannucci P M, Gringeri A et al.. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.  Transfusion. 1997;  37 517-522
    CrossrefPubMedGoogle Scholar
  • 14 Croghan D L, Matchett A, Koski T A. Isolation of porcine parvovirus from commercial trypsin.  Appl Microbiol. 1973;  26 431-433
    PubMedGoogle Scholar
  • 15 Blumel J, Schmidt I, Effenberger W et al.. Parvovirus B19 transmission by heat-treated clotting factor concentrates.  Transfusion. 2002;  42 1473-1481
    CrossrefPubMedGoogle Scholar
  • 16 Wu C G, Mason B, Jong J et al.. Parvovirus B19 transmission by a high-purity factor VIII concentrate.  Transfusion. 2005;  45 1003-1010
    CrossrefPubMedGoogle Scholar
  • 17 Chae C. A review of porcine circovirus 2-associated syndromes and diseases.  Vet J. 2005;  169 326-336
    CrossrefPubMedGoogle Scholar
  • 18 Miller M M, Schat K A. Chicken infectious anemia virus: an example of the ultimate host-parasite relationship.  Avian Dis. 2004;  48 734-745
    PubMedGoogle Scholar
  • 19 Bendinelli M, Pistello M, Maggi F et al.. Molecular properties, biology, and clinical implications of TT virus, a recently identified widespread infectious agent of humans.  Clin Microbiol Rev. 2001;  14 98-113
    CrossrefPubMedGoogle Scholar
  • 20 Graham C S, Baden L R, Yu E et al.. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.  Clin Infect Dis. 2001;  33 562-569
    CrossrefPubMedGoogle Scholar
  • 21 Greub G, Ledergerber B, Battegay M et al.. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.  Lancet. 2000;  356 1800-1805
    CrossrefPubMedGoogle Scholar
  • 22 Beers M H, Berkow R B. The Merck Manual of Diagnosis and Therapy. Section 13, Chapter 163. Human immunodeficiency virus infection. Merck & Co. Available at: http://www.merck.com/mrkshared/mmanuel/home.jsp Accessed June 1, 2005
    Google Scholar
  • 23 Canavese C, Hollo Z, Ciccone G et al.. Extrahepatic immunological manifestations of hepatitis C virus in dialysis patients.  J Nephrol. 2000;  13 352-359
    PubMedGoogle Scholar
  • 24 Alter M J, Kruszon-Moran D, Nainan O V et al.. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.  N Engl J Med. 1999;  341 556-562
    CrossrefPubMedGoogle Scholar
  • 25 Melvin D C, Lee J K, Belsey E, Arnold J, Murphy R L. The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy.  AIDS. 2000;  14 463-465
    PubMedGoogle Scholar
  • 26 Palella Jr F J, Delaney K M, Moorman A C et al.. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.  N Engl J Med. 1998;  338 853-860
    CrossrefPubMedGoogle Scholar
  • 27 Darby S C, Ewart D W, Giangrande P L et al.. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation.  Lancet. 1997;  350 1425-1431
    CrossrefPubMedGoogle Scholar
  • 28 Torriani F J, Rodriguez-Torres M, Rockstroh J K et al.. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.  N Engl J Med. 2004;  351 438-450
    CrossrefPubMedGoogle Scholar
  • 29 Beisel C E, Morens D M. Variant Creutzfeldt-Jakob disease and the acquired and transmissible spongiform encephalopathies.  Clin Infect Dis. 2004;  38 697-704
    CrossrefPubMedGoogle Scholar
  • 30 Brown P, Will R G, Bradley R, Asher D M, Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns.  Emerg Infect Dis. 2001;  7 6-16
    PubMedGoogle Scholar
  • 31 Will R G, Ironside J W, Zeidler M et al.. A new variant of Creutzfeldt-Jakob disease in the UK.  Lancet. 1996;  347 921-925
    CrossrefPubMedGoogle Scholar
  • 32 NCJDSU .The National Creutzfeldt-Jakob Disease Surveillance Unit. CJD statistics. Available at: http://www.cjd.ed.ac.uk/figures.htm Accessed October 3, 2005
    Google Scholar
  • 33 Peden A H, Head M W, Ritchie D L, Bell J E, Ironside J W. Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient.  Lancet. 2004;  364 527-529
    CrossrefPubMedGoogle Scholar
  • 34 Ghani A C, Donnelly C A, Ferguson N M, Anderson R M. Updated projections of future vCJD deaths in the UK.  BMC Infect Dis. 2003;  3 4
    CrossrefPubMedGoogle Scholar
  • 35 Nix P. Prions and disposable surgical instruments.  Int J Clin Pract. 2003;  57 678-680
    PubMedGoogle Scholar
  • 36 Houston F, Foster J D, Chong A, Hunter N, Bostock C J. Transmission of BSE by blood transfusion in sheep.  Lancet. 2000;  356 999-1000
    CrossrefPubMedGoogle Scholar
  • 37 Llewelyn C A, Hewitt P E, Knight R S et al.. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion.  Lancet. 2004;  363 417-421
    CrossrefPubMedGoogle Scholar
  • 38 Sachse C, Groschup M H, Warzok R, Greinacher A. Role of variant Creutzfeldt-Jakob disease for safety of treatment with blood components: screening of lymphatic tissue is a potential tool for risk assessment.  Eur J Haematol. 2003;  70 11-16
    CrossrefPubMedGoogle Scholar
  • 39 Brown P, Rohwer R G, Dunstan B C et al.. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy.  Transfusion. 1998;  38 810-816
    CrossrefPubMedGoogle Scholar
  • 40 Hunter N, Foster J, Chong A et al.. Transmission of prion diseases by blood transfusion.  J Gen Virol. 2002;  83 2897-2905
    CrossrefPubMedGoogle Scholar
  • 41 Communicable Disease Report Weekly . New case of transfusion-associated variant-CJD.  CDR Weekly. 2006;  9(Feb) 1
    PubMedGoogle Scholar
  • 42 Ironside J W. The spectrum of safety: variant Creutzfeldt-Jakob disease in the United Kingdom.  Semin Hematol. 2003;  40 16-22
    CrossrefPubMedGoogle Scholar
  • 43 UKHCDO . Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders.  Haemophilia. 2003;  9 1-23
    PubMedGoogle Scholar

 Dr.
Richard Knight

National CJD Surveillance Unit

Crewe Road, Edinburgh, UK EH4 2XU

Email: v1rknigh@staffmail.ed.ac.uk

      >